Observational study for newly diagnosed MZL
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study is for people who were just diagnosed with marginal zone lymphoma (a slow-growing blood cancer) and haven't started treatment yet. Researchers will collect blood and tissue samples and follow you over time to learn more about the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have been diagnosed with marginal zone lymphoma in the last 6 months.
- You have not had any cancer treatment (like chemotherapy, radiation, or immunotherapy) yet.
- You are willing to give blood and tumor tissue samples.
- You can commit to long-term follow-up visits at the hospital.
- You do not have HIV.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is a registry that collects information on Chinese patients with marginal zone lymphoma. It helps doctors learn more about how MZL behaves and how it is treated.
This trial studies whether obinutuzumab combined with lenalidomide can control marginal zone lymphoma that has come back or not responded to prior treatment. If you qualify, you may receive these medicines together to help shrink tumors and improve symptoms.
This trial compares a combination of mosunetuzumab and lenalidomide against standard treatments for people with marginal zone lymphoma that has come back or stopped responding to previous therapy. It aims to find out if the new combination works better than current options.
This trial tests a combination of two medicines—pirtobrutinib (a targeted pill) and rituximab (an infusion)—for people with marginal zone lymphoma who have not had any prior systemic treatment. The goal is to see if this combination works better than standard treatments.
This trial tests a personalized treatment plan for people with newly diagnosed marginal zone lymphoma (MZL). The treatment is based on a risk score and aims to be more targeted than standard chemotherapy.
This study collects and analyzes tumor samples from people with nodal marginal zone lymphoma to better understand the disease and predict outcomes. It may help doctors characterize the lymphoma more accurately using clinical and lab information.
Hear when a new Marginal Zone Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.